临床参数对Ⅳ期非小细胞肺癌一线EGFR-TKIs疗效的预测价值

郑林鹏; 许子寒; 朱广阔; 李奉; 杨峤; 余永新; 孙建国

doi:10.16016/j.1000-5404.201809143

您当前的位置：

首页 >

文章列表页 >

临床参数对Ⅳ期非小细胞肺癌一线EGFR-TKIs疗效的预测价值

临床医学 | 更新时间：2026-01-09

- 临床参数对Ⅳ期非小细胞肺癌一线EGFR-TKIs疗效的预测价值
- Predictive value of clinical parameters in responses to epidermal growth factor-tyrosine kinase inhibitors as first-line therapy for stage Ⅳ non-small cell lung cancer
- 第三军医大学学报 2019年41卷第4期页码：346-352
- 作者机构：
  
  400037 重庆，陆军军医大学(第三军医大学)第二附属医院全军肿瘤研究所
- 作者简介：
  
  [ 孙建国，E-mail: sunjg09@aliyun.com SUN Jianguo, E-mail: sunjg09@aliyun.com
- 基金信息：
  
  国家自然科学基金面上项目(81672841);第三军医大学附属新桥医院临床科研项目(2014YLC08)
- DOI：10.16016/j.1000-5404.201809143
  中图分类号： R734.2;R969.4;R979.1
- 收稿：2018-09-20，
  
  修回：2018-11-01，
  
  纸质出版：2019-02-28
- 稿件说明：
移动端阅览
郑林鹏, 许子寒, 朱广阔, 等. 临床参数对Ⅳ期非小细胞肺癌一线EGFR-TKIs疗效的预测价值[J]. 第三军医大学学报, 2019,41(4):346-352.

Linpeng ZHENG, Zihan XU, Guangkuo ZHU, et al. Predictive value of clinical parameters in responses to epidermal growth factor-tyrosine kinase inhibitors as first-line therapy for stage Ⅳ non-small cell lung cancer[J]. Journal of Third Military Medical University, 2019, 41(4): 346-352.
郑林鹏, 许子寒, 朱广阔, 等. 临床参数对Ⅳ期非小细胞肺癌一线EGFR-TKIs疗效的预测价值[J]. 第三军医大学学报, 2019,41(4):346-352. DOI： 10.16016/j.1000-5404.201809143.

Linpeng ZHENG, Zihan XU, Guangkuo ZHU, et al. Predictive value of clinical parameters in responses to epidermal growth factor-tyrosine kinase inhibitors as first-line therapy for stage Ⅳ non-small cell lung cancer[J]. Journal of Third Military Medical University, 2019, 41(4): 346-352. DOI： 10.16016/j.1000-5404.201809143.

摘要

目的

通过分析临床参数与表皮生长因子受体酪氨酸激酶抑制剂(epidermal growth factorreceptor-tyrosine kinase inhibitors

EGFR-TKIs)疗效的关系，为一线Ⅳ期非小细胞肺癌(non-small cell lung cancer，NSCLC)EGFR-TKIs治疗疗效寻找简易的标志物。

方法

回顾性分析2010-2016年在本院接受一线EGFR-TKIs (厄洛替尼、吉非替尼、埃克替尼)治疗的Ⅳ期EGFR阳性突变NSCLC患者的临床参数与疗效的关系。

结果

共纳入123例，其中男性43例，女性80例，年龄28~84岁，客观缓解率(objective response rate，ORR)47.97%，疾病控制率(disease control rate，DCR)100%，中位无进展生存期(median progression-free survival，mPFS)11.0个月，中位总生存期(median overall survival，mOS) 22.7个月。单因素分析显示治疗前低NSE、CA125或Cyfra21-1者PFS较长(14.2

9.1个月，

0.001；12.4

9.5个月，

=0.024；12.3

9.5个月，

=0.033)。而PS评分0~1分，低NSE、CA125、Cyfra21-1或CA15-3者OS较长(mOS：24.0

16.5个月，

=0.001；27.7

17.3个月，

0.001；25.4

20.2个月，

=0.002；25.7

18.1个月，

=0.027；25.5

18.7个月，

=0.009)。多因素分析结果显示CA125和NSE是PFS的独立影响因素，而CA125、NSE、CA15-3、肝转移、PS评分是OS的独立影响因素。CA125、Cyfra21-1、CA15-3和NSE 4个参数中多个参数升高的PFS、OS较单个参数升高短(mPFS：9.3

11.8个月，

=0.045；mOS：18.7

27.4个月，

=0.001)。

结论

治疗前低水平的CA125或NSE预示着Ⅳ期NSCLC一线EGFR-TKIs治疗的PFS较长，而PS评分0~1分

低水平的NSE、CA125或CA15-3则预示OS较长。CA125、Cyfra21-1、CA15-3和NSE 4个临床参数联合有望成为预测Ⅳ期NSCLC一线EGFR-TKIs疗效的简易标志物。

Abstract

Objective

To analyze the relationship between the clinical parameters and the efficacy of epidermal growth factorreceptor-tyrosine kinase inhibitors (EGFR-TKIs) as the first-line therapy in patients with stage Ⅳ non-small cell lung cancer (NSCLC) and identify the clinical markers for predicting the patients' responses to the treatment.

Methods

The clinical data were retrospectively reviewed for the patients with stage Ⅳ EGFR mutation-positive NSCLC receiving EGFR-TKIs (erlotinib

gefitinib

and icotinib) as the first-line therapy in our hospital between January

2010 and December

2016

and the relationship between the patients' clinical parameters and responses to the treatment were analyzed.

Results

A total of 123 patients (43 males and 80 females

aged ranging from 28 to 84 years) were included in this study. The objective response rate (ORR) of the overall patients was 47.97%

the disease control rate (DCR) was 100%

the median progression-free survival (mPFS) time was 11.0 months

and the median overall survival (OS) time was 22.7 months. Univariate analysis showed that the patients with low levels of neuronspecific enolase (NSE)

carbohydrate antigen 125 (CA125) or Cyfra21-1 before the treatment had significantly prolonged mPFS time (NES: 14.2

9.1 months

0.001; CA125: 12.4

9.5 months

=0.024; Cyfra21-1: 12.3

9.5 months

=0.033); the mOS time was significantly prolonged in patients with ECOG performance status of 0~1 (24.0

16.5 months

=0.001) and low levels of NSE (27.7

17.3 months

0.001)

CA125 (25.4

20.2 months

=0.002)

Cyfra21-1 (25.7

18.1 months

=0.027) or CA15-3 (25.5

18.7 months

=0.009). Multivariate analysis suggested that CA125 and NSE were independent prognostic factors of PFS

and CA125

NSE

CA15-3

hepatic metastasis and performance status were independent prognostic factors of the OS time. Combined analysis of CA125

Cyfra21-1

CA15-3 and NSE showed that compared with those with elevation of a single factor

the patients with elevation of multiple factors had shorter mPFS time (9.3

11.8 months

=0.045) and also shorter mOS time (18.7

27.4 months

=0.001).

Conclusion

Low levels of CA125 or NSE before first-line EGFR-TKIs treatment are associated with longer PFS time of the patients with stage Ⅳ NSCLC

while performance status of 0~1 and low levels of NSE

CA125 or CA15-3 are associated with a longer OS time of the patients. The combination of CA125

Cyfra21-1

CA15-3 and NSE is expected to serve as a simple indicator for predicting the efficacy of firstreceptor-line EGFR-TKIs therapy in patients with stage Ⅳ NSCLC.

关键词

Keywords

references

CHEN W, ZHENG R, BAADE P D, et al . Cancer statistics in China, 2015[J ] . CA Cancer J Clin, 2016, 66(2): 115-132. DOI: 10.3322/caac.21338.

MOK T S, WU Y L, THONGPRASERT S, et al . Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma[J ] . N Engl J Med, 2009, 361(10): 947-957. DOI: 10.1056/NEJMoa0810699.

WU Y L, ZHOU C, LIAM C K, et al . First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase Ⅲ, randomized, open-label, ENSURE study[J ] . Ann Oncol, 2015, 26(9): 1883-1889. DOI: 10.1093/annonc/mdv270.

SHI Y K, WANG L, HAN B H, et al . First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study[J ] . Ann Oncol, 2017, 28(10): 2443-2450. DOI: 10.1093/annonc/mdx359.

LIN G N, PENG J W, LIU P P, et al . Elevated neutrophil-to-lymphocyte ratio predicts poor outcome in patients with advanced non-small-cell lung cancer receiving first-line gefitinib or erlotinib treatment[J ] . Asia Pac J Clin Oncol, 2017, 13(5): e189-e194. DOI: 10.1111/ajco.12273.

LI H, WANG Y, SU F, et al . Monitoring of cyclooxygenase-2 levels can predict EGFR mutations and the efficacy of EGFR-TKI in patients with lung adenocarcinoma[J ] . Int J Clin Exp Pathol, 2015, 8(5): 5577-5583.

FIALA O, PESEK M, FINEK J, et al . Change in serum lactate dehydrogenase is associated with outcome of patients with advanced-stage NSCLC treated with erlotinib[J ] . Anticancer Res, 2016, 36(5): 2459-2465. DOI: 10.1007/s13277- 015-3660-3.

SOCINSKI M A, JOTTE R M, CAPPUZZO F, et al . Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC[J ] . N Engl J Med, 2018, 378(24): 2288-2301. DOI: 10.1056/NEJMoa1716948.

SUH K J, KEAM B, KIM M, et al . Serum neuron-specific enolase levels predict the efficacy of first-line epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring EGFR mutations[J ] . Clin Lung Cancer, 2016, 17(4): 245-252. e1.DOI: 10.1016/j.cllc.2015.11.012.

JØRGENSEN L G, OSTERLIND K, GENOLL J, et al . Serum neuron-specific enolase (S-NSE) and the prognosis in small-cell lung cancer (SCLC): a combined multivariable analysis on data from nine centres[J ] . Br J Cancer, 1996, 74(3): 463-467.

JØRGENSEN L G, OSTERLIND K, HANSEN H H, et al . Serum neuron-specific enolase (S-NSE) in progressive small-cell lung cancer (SCLC)[J ] . Br J Cancer, 1994, 70(4): 759-761.

BONNER J A, SLOAN J A, ROWLAND KM Jr, et al . Significance of neuron-specific enolase levels before and during therapy for small cell lung cancer[J ] . Clin Cancer Res, 2000, 6(2): 597-601.

YESNER R, CARTER D. Pathology of carcinoma of the lung. Changing patterns[J]. Clin Chest Med, 1982, 3(2): 257-289.

OSER M G, NIEDERST M J, SEQUIST L V, et al . Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin[J ] . Lancet Oncol, 2015, 16(4): e165-e172. DOI: 10.1016/S1470- 2045(14)71180-5.

PUJOL J L, GRENIER J, DAUR S J P, et al . Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer[J ] . Cancer Res, 1993, 53(1): 61-66.

SHUKUYA T, TAKAHASHI T, KAIRA R, et al . Efficacy of gefitinib for non-adenocarcinoma non-small-cell lung cancer patients harboring epidermal growth factor receptor mutations: a pooled analysis of published reports[J ] . Cancer Sci, 2011, 102(5): 1032-1037. DOI: 10.1111/j.1349- 7006.2011.01887.x.

TAKEUCHI A, OGURI T, SONE K, et al . Predictive and prognostic value of CYFRA 21-1 for advanced non-small cell lung cancer treated with EGFR-TKIs[J ] . Anticancer Res, 2017, 37(10): 5771-5776. DOI: 10.21873/anticanres.12018.

FERRARO S, ROBBIANO C, TOSCA N, et al . Serum human epidi dymis protein 4 vs carbohydrate antigen 125 in ovarian cancer follow-up[J ] . Clin Biochem, 2018, 60: 84-90. DOI: 10.1016/j.clinbiochem.2018.08.003..

SCHMIDT M, SEGEV Y, SADEH R, et al . Cancer antigen 125 levels are significantly associated with prognostic parameters in uterine papillary serous carcinoma[J ] . Int J Gynecol Cancer, 2018, 28(7): 1311-1317. DOI: 10.1097/IGC.0000000000001300.

NAKATA B, HIRAKAWA-YS CHUNG K, KATO Y, et al . Serum CA 125 level as a predictor of peritoneal dissemination in patients with gastric carcinoma[J ] . Cancer, 1998, 83(12): 2488-2492.

陈含笑, 杨雪, 刘慧君, 等.血清肿瘤标志物与一线EGFR-TKIs治疗晚期EGFR突变型肺腺癌患者疗效相关性分析[J].中国肺癌杂志, 2017, 20(9): 589-597. DOI: 10.3779/j.issn.1009-3419.2017.09.01.

CHEN H X, YANG X, LIU H J, et al . Correlation between serum tumor markers and efficacy of first-line EGFR-TKIs in patients with advanced lung adenocarcinoma[J ] . Chin J Lung Cancer, 2017, 20(9): 589-597. DOI: 10.3779/j.issn. 1009-3419.2017.09.01.

KIMURA Y, FUJⅡ T, HAMAMOTO K, et al . Serum CA125 level is a good prognostic indicator in lung cancer[J ] . Br J Cancer, 1990, 62(4): 676-678. DOI: 10.1038/bjc.1990.355.

SHAO Y, SUN X, HE Y, et al . Elevated levels of serum tumor markers CEA and CA15-3 are prognostic parameters for different molecular subtypes of breast cancer[J ] . PLoS ONE, 2015, 10(7): e133830. DOI: 10.1371/journal.pone.0133830.

WU S G, HE Z Y, ZHOU J, et al . Serum levels of CEA and CA15-3 in different molecular subtypes and prognostic value in Chinese breast cancer[J ] . Breast, 2014, 23(1): 88-93. DOI: 10.1016/j.breast.2013.11.003.

Integrative Analysis of Lung Cancer Etiology and Risk (INTEGRAL) Consortium for Early Detection of Lung Cancer. Assessment of lung cancer risk on the basis of a biomarker panel of circulating proteins[J]. JAMA Oncol, 2018, 4(10): e182078. DOI: 10.1001/jamaoncol.2018.2078.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

表皮生长因子受体酪氨酸激酶抑制剂在非小细胞肺癌治疗的研究进展及展望

264例肺腺癌患者EGFR基因突变及TKI类药物临床疗效分析

晚期非小细胞肺癌不同含铂两药方案一线化疗预后因素的分析

非小细胞肺癌ERCC1 C118T多态性与EGFR突变的相关性

层粘蛋白和钙调素蛋白在非小细胞肺癌中的表达及其与转移和预后的关系